Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study

A. C. Altamura, M. C. Mauri, M. Mantero, M. Brunetti

Research output: Contribution to journalArticlepeer-review


Clonazepam (CLN), a benzodiazepine originally used as an anti-epileptic, was tested in schizophrenia in a double blind comparison in combination with haloperidol (HL). Twenty-four schizophrenic inpatients, diagnosed according to DSM III were treated with HL and CLN (Group I) or HL and placebo (Group 2) for 4 weeks. The Brief Psychiatric Rating Scale (BPRS) and the Extrapyrimidal Side Effect Scale (EPSE) were used for assessing psychopathological features and extra-pyramidal side-effects before treatment and then weekly. No differences in specific schizophrenic symptoms were detected between the two groups, but in Group 1 an early significant BPRS amelioration was noticed compared in Group 2. Moreover, the excitement item improved singificantly in Group 1 only, from the second week. Less severe EPSE scores were observed in Group 1 in comparison to Group 2. In conclusion the combination of CLN and HL seems to be preferred to HL alone in cases of psychotic excitement and in order to reduce the severity of extrapyramidal side-effects.

Original languageEnglish
Pages (from-to)702-706
Number of pages5
JournalActa Psychiatrica Scandinavica
Issue number6
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)


Dive into the research topics of 'Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study'. Together they form a unique fingerprint.

Cite this